Want to see PCRX full AI Analyst Report?
Total Valuation
Pacira Pharmaceuticals has a market cap or net worth of $1.06B. The enterprise value is $1.13K.
Market Cap$1.06B
Enterprise Value$1.13K
Share Statistics
Pacira Pharmaceuticals has 39,334,984 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding39,334,984
Owned by Insiders3.73%
Owned by Institutions3.00%
Financial Efficiency
Pacira Pharmaceuticals’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 1.20%.
Return on Equity (ROE)0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)1.20%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee880.50K
Profits Per Employee8.53K
Employee Count825
Asset Turnover0.57
Inventory Turnover0.98
Valuation Ratios
The current PE Ratio of Pacira Pharmaceuticals is 216.3. Pacira Pharmaceuticals’s PEG ratio is -1.51.
PE Ratio216.3
PS Ratio1.59
PB Ratio1.66
Price to Fair Value1.66
Price to FCF8.44
Price to Operating Cash Flow7.51
PEG Ratio-1.51
Income Statement
In the last 12 months, Pacira Pharmaceuticals had revenue of 726.41M and earned 7.03M in profits. Earnings per share was 0.16.
Revenue726.41M
Gross Profit576.66M
Operating Income33.30M
Pretax Income16.87M
Net Income7.03M
EBITDA122.50M
Earnings Per Share (EPS)0.16
Cash Flow
In the last 12 months, operating cash flow was 142.22M and capital expenditures -9.51M, giving a free cash flow of 132.71M billion.
Operating Cash Flow142.22M
Free Cash Flow132.71M
Free Cash Flow per Share3.37
Dividends & Yields
Pacira Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.78
52-Week Price Change19.66%
50-Day Moving Average24.43
200-Day Moving Average23.48
Relative Strength Index (RSI)62.30
Average Volume (3m)495.81K
Important Dates
Pacira Pharmaceuticals upcoming earnings date is Aug 4, 2026, Before Open (Confirmed).
Last Earnings DateApr 30, 2026
Next Earnings DateAug 4, 2026
Ex-Dividend Date―
Financial Position
Pacira Pharmaceuticals as a current ratio of 4.54, with Debt / Equity ratio of 62.88%
Current Ratio4.54
Quick Ratio3.28
Debt to Market Cap0.36
Net Debt to EBITDA2.41
Interest Coverage Ratio2.28
Taxes
In the past 12 months, Pacira Pharmaceuticals has paid 9.84M in taxes.
Income Tax9.84M
Effective Tax Rate0.58
Enterprise Valuation
Pacira Pharmaceuticals EV to EBITDA ratio is 11.83, with an EV/FCF ratio of 10.60.
EV to Sales2.00
EV to EBITDA11.83
EV to Free Cash Flow10.60
EV to Operating Cash Flow9.53
Balance Sheet
Pacira Pharmaceuticals has $202.18M in cash and marketable securities with $411.18M in debt, giving a net cash position of -$209.00M billion.
Cash & Marketable Securities$202.18M
Total Debt$411.18M
Net Cash-$209.00M
Net Cash Per Share-$5.31
Tangible Book Value Per Share$6.84
Margins
Gross margin is 79.34%, with operating margin of 4.58%, and net profit margin of 0.97%.
Gross Margin79.34%
Operating Margin4.58%
Pretax Margin2.32%
Net Profit Margin0.97%
EBITDA Margin16.86%
EBIT Margin4.33%
Analyst Forecast
The average price target for Pacira Pharmaceuticals is $31.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$31.67
Price Target Upside22.36% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast4.57%
EPS Growth Forecast―